« Return to News | Awards & Advancement

Firecrest Clinical Appoints New CEO

Thursday, May 20, 2010 09:06 AM

Firecrest Clinical, an eClinical solution provider, announces the appointment of Alan Horgan as CEO.

Horgan began working in the drug development sector in 1997 and moved to the United States in 2000. In 2009, he began working with Firecrest to establish their operations in the U.S. and globalize their business. 

Possessing many years of experience within the pharmaceutical industry, Horgan has held several high-level positions in the healthcare clinical research organization (CRO) sector, most notably at MDS Pharma Services as group vice president, late stage development, and at Covance as corporate senior vice president and president, clinical development. His broad experience of clinical development and the challenges of running complex global clinical trials make him well suited to build on the strong foundations that Firecrest has established in Europe and the U.S. 

Horgan stated that he has “found a company that truly addresses the needs of the principal investigators and their busy site staff. It is easy to forget that, as trials continue to become more complex, finding suitable patients and recording many thousands of pieces of data becomes increasingly difficult. This continues to be a challenge despite the introduction of various technologies designed ostensibly in recent years to simplify the process.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.